Small and mid-sized biotech companies face unique challenges when bringing novel therapies to market. While many large pharmaceutical companies have the knowledge and in-house talent to clear regulatory hurdles and conduct efficient clinical trials, smaller companies often do not. That’s why small and mid-sized biotechs need to THINK BIG when working to deliver life-changing therapies to patients with unmet needs.
Join seasoned experts as they share successful strategies they’ve used to help small and mid-sized companies get innovative treatments to the people who need them. Each episode in our three-part series is packed with insights and practical tips for success.
Check out the podcast episodes below.
⬆- Ep. 3 Operationalizing Cell and Gene Therapy Trials
- Ep. 2 Why Multinational Clinical Trials Are Key to Bringing Novel Therapies to Market
- Ep. 1 Defining the Regulatory Roadmap for Product Success
Ep. 3
Operationalizing Cell and Gene Therapy Trials
In the third and final episode, Desmond Cabrera, global lead for cell and gene therapy at Allucent, shares how small- and mid-sized companies can operationalize cell and gene therapy trials.